Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Considerations for Long-Acting Injectable PrEP

Source: Key Decisions in HIV Care
Listen as Jason Schafer, PharmD, MPH, shares key considerations for using long-acting injectable cabotegravir for PrEP, including management of missed dosing, stopping PrEP, and screening for HIV while receiving PrEP.
person default
Jason Schafer, PharmD, MPH
Released: March 21, 2022

In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).

Listen as he gives his perspectives on:

  • The FDA approval of long-acting cabotegravir for PrEP
  • Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy
  • Considerations for long-acting cabotegravir as PrEP
    • Dosing and administration
    • Managing missed doses
    • Discontinuation
    • Delays in HIV diagnoses found in the HPTN 083 study in men
  • CDC recommendations for HIV screening while receiving PrEP

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Information on this Educational Activity

Faculty

Jason Schafer, PharmD, MPH

Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Jason Schafer, MD, MPH, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Merck and ViiV.

Program Medium

This program has been made available online.

Related Content

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Gregory Huhn, MD, MPHTM Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: June 17, 2022 Expired: June 16, 2023

Clinical Care Options (CCO) downloadable slides from Dr Darrell Tan, providing an overview of available long-acting ART for HIV treatment and prevention

Babafemi Taiwo, MBBS
Program Director Darrell H. S. Tan, MD, FRCPC, PhD Released: June 14, 2022

Clinical Care Options (CCO) downloadable slides from Cristina Mussini, MD, providing practical insights into implementing long-acting ART into HIV care

Babafemi Taiwo, MBBS
Program Director Cristina Mussini, MD Released: June 14, 2022

Clinical Care Options (CCO) downloadable slides from Yvonne Gilleece providing an overview of investigational long-acting HIV care and prevention approaches

Babafemi Taiwo, MBBS
Program Director person default Yvonne Gilleece, MB BCh, BAO Released: June 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings